All In Biotech

NDA 215760 · Orphalan

Cuvrior

Trientine Tetrahydrochloride · Oral

Orphan

Last checked: Nov 19, 2026Latest source record: Apr 28, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Apr 28, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

3

2 Phase 3, 1 recruiting

FAERS reports

307

106 serious, 13 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 19, 2025.

CUVRIOR is indicated for the treatment of adult patients with stable Wilson's disease who are de-coppered and tolerant to penicillamine. CUVRIOR is a copper chelator indicated for the treatment of adult patients with stable Wilson's disease who are de-coppered and tolerant to penicillamine. ( 1 )

Mechanism: Trientine, a copper chelator, eliminates absorbed copper from the body by forming a stable complex that is then eliminated through urinary excretion. Trientine also chelates copper in the intestinal tract, reducing copper absorption.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 28, 2022 Original approval · Type 2 - New Active Ingredient OrphanLabelLetterReview
1 products under this application
  • CUVRIOR · TRIENTINE TETRAHYDROCHLORIDE 300MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Trientine Tetrahydrochloride" as an intervention, any sponsor and status, largest first.

All 3 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use79
  • product dose omission issue71
  • nausea22
  • treatment noncompliance21
  • malaise10
  • abdominal pain upper9
  • fatigue9
  • maternal exposure during pregnancy9
  • nasopharyngitis9
  • vomiting9
  • abdominal pain8
  • tremor8

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20171
20222
202321
202486
2025162
202635

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cuvrior (Trientine Tetrahydrochloride)

2024 spending

$1.6M

Beneficiaries

13

86 claims

Per beneficiary

$119,998

$201.86 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$378,237
2024$1,559,973

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3 on PubMed

Sponsor: Orphalan

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.